Teva
Global Generic Pharmaceuticals Company.
Launch date
Employees
Market cap
€18.4b
Enterprise valuation
€33.6b (Public information from Sep 2024)
Share price
$17.88 TEVA
Petah Tikva Center District (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 16.9b | 16.7b | 15.9b | 14.9b | 15.8b | 16.2b | 16.8b |
% growth | (8 %) | (1 %) | (5 %) | (6 %) | 6 % | 2 % | 3 % |
EBITDA | 3.2b | 4.6b | 4.5b | 4.1b | 4.3b | - | - |
% EBITDA margin | 19 % | 28 % | 29 % | 28 % | 27 % | - | - |
Profit | (999m) | (4.0b) | 417m | (2.4b) | (559m) | - | - |
% profit margin | (6 %) | (24 %) | 3 % | (16 %) | (4 %) | - | - |
R&D budget | 1.0b | 997m | 967m | 838m | 953m | - | - |
R&D % of revenue | 6 % | 6 % | 6 % | 6 % | 6 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | N/A | IPO | |
$358m | Post IPO Equity | ||
* | $12.0m | Post IPO Equity | |
Total Funding | - |
Related Content
Recent News about Teva
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Teva
Editexited
exited
ACQUISITION by Roche Dec 2017
ACQUISITION by Teva Jul 2015
ACQUISITION by Biozone Pharmaceuticals Jan 2014
ACQUISITION by Teva May 2011
ACQUISITION by Sosei Group Feb 2015
ACQUISITION by Teva Mar 2015
exited